149 related articles for article (PubMed ID: 12841684)
1. Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells.
Unlü A; Leake RE
Int J Biol Markers; 2003; 18(2):147-51. PubMed ID: 12841684
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Pasini FS; Brentani MM; Kowalski LP; Federico MH
Head Neck; 2001 Sep; 23(9):725-32. PubMed ID: 11505481
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells.
Dong-Le Bourhis X; Lambrecht V; Boilly B
Br J Cancer; 1998; 77(3):396-403. PubMed ID: 9472634
[TBL] [Abstract][Full Text] [Related]
4. Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.
He C; He P; Liu LP; Zhu YS
J Cancer Res Clin Oncol; 2001; 127(3):180-6. PubMed ID: 11260863
[TBL] [Abstract][Full Text] [Related]
5. Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic-cancer cell lines.
Desruisseau S; Ghazarossian-Ragni E; Chinot O; Martin PM
Int J Cancer; 1996 Jun; 66(6):796-801. PubMed ID: 8647652
[TBL] [Abstract][Full Text] [Related]
6. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
Lyon PB; See WA; Xu Y; Cohen MB
Prostate; 1995 Oct; 27(4):179-86. PubMed ID: 7479384
[TBL] [Abstract][Full Text] [Related]
7. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
[TBL] [Abstract][Full Text] [Related]
8. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.
Farina AR; Coppa A; Tiberio A; Tacconelli A; Turco A; Colletta G; Gulino A; Mackay AR
Int J Cancer; 1998 Mar; 75(5):721-30. PubMed ID: 9495240
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.
Hirashima Y; Kobayashi H; Suzuki M; Tanaka Y; Kanayama N; Terao T
J Biol Chem; 2003 Jul; 278(29):26793-802. PubMed ID: 12743121
[TBL] [Abstract][Full Text] [Related]
12. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
13. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Arnoletti JP; Albo D; Granick MS; Solomon MP; Castiglioni A; Rothman VL; Tuszynski GP
Cancer; 1995 Sep; 76(6):998-1005. PubMed ID: 8625226
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Gris JC; Schved JF; Marty-Double C; Mauboussin JM; Balmes P
Chest; 1993 Jul; 104(1):8-13. PubMed ID: 7686838
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
Ito H; Yonemura Y; Fujita H; Tsuchihara K; Kawamura T; Nojima N; Fujimura T; Nose H; Endo Y; Sasaki T
Virchows Arch; 1996 Feb; 427(5):487-96. PubMed ID: 8624578
[TBL] [Abstract][Full Text] [Related]
16. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells.
Festuccia C; Angelucci A; Gravina GL; Villanova I; Teti A; Albini A; Bologna M
Int J Cancer; 2000 Feb; 85(3):407-15. PubMed ID: 10652434
[TBL] [Abstract][Full Text] [Related]
17. [The plasma levels of transforming growth factor beta1 and the protein expressions of alpha-SMA, urokinase plasminogen activator and plasminogen activator inhibitor-1 in liver of patients with different grades of hepatic fibrosis].
Wu XR; Lv MH; Wang Q; Shi SS; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):400-2. PubMed ID: 15268802
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
19. The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
Thewes M; Elsner E; Wessner D; Engst R; Ring J
Int J Dermatol; 2000 Mar; 39(3):188-91. PubMed ID: 10759957
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
